Andy Studna, Senior Editor

Ira C. Spector, PhD, MBA, CEO and Co-Founder, SFA Therapeutics discusses how his career journey has epitomized the ability to solve problems, which is essentially the role of drug development. It has also led to the formation and strategic approach to his company’s early-stage clinical trials for using the microbiome to address chronic inflammatory diseases.

Beth MacEntee Pileggi, Head of Global Case and Safety Data Management with Janssen Pharmaceuticals of Johnson & Johnson, and Co-Lead of TransCelerate’s Pharmacovigilance Agreements Optimization Initiative, discusses the importance of safety, collaboration, TransCelerate’s positive role in the pharma industry and her passion for PV.

Melissa Easy, VP and GM, clinical technologies at IQVIA speaks about concerns with clinical technology at the SCOPE 2023 conference in Orlando, FL.

Melissa Easy, VP and GM, clinical technologies at IQVIA speaks about what should be top of mind for clinops professionals in 2023 at the SCOPE 2023 conference in Orlando, FL.

Sunny Kumar, MD, partner at GSR Ventures speaks about reducing hospital readmissions for high-risk patients at the SCOPE 2023 conference in Orlando, FL.

Sunny Kumar, MD, partner at GSR Ventures speaks about venture capital in clinical research at the SCOPE 2023 conference in Orlando, FL.

Joan Chambers, senior director of marketing, communication & education at CISCRP notes her key takeaways from the SCOPE 2023 conference in Orlando, FL.

Joan Chambers, senior director of marketing, communication & education for CISCRP reveals what innovations are coming up at the SCOPE 2023 conference in Orlando, FL.

Joan Chambers, senior director of marketing, communication & education for CISCRP comments on current CISCRP happenings at the SCOPE 2023 conference in Orlando, FL.

Joan Chambers, senior director of marketing, communication & education for CISCRP names the three biggest challenges facing clinical trials at the SCOPE 2023 conference in Orlando, FL.

Murray L. Aitken, SVP of IQVIA offers insights that small biopharma organizations can take away from larger companies at the SCOPE 2023 conference in Orlando, FL.

Sunny Kumar, MD, partner at GSR Ventures speaks about how healthcare and clinical trials can work together to create a greater impact at the SCOPE 2023 conference in Orlando, FL.

Sunny Kumar, MD, partner at GSR Ventures speaks about areas of investment in clinical trials at the SCOPE 2023 conference in Orlando, FL.

Murray L. Aitken, SVP of IQVIA speaks about the concerns of smaller biopharma companies getting into clinical trials at the SCOPE 2023 conference in Orlando, FL.

Murray L. Aitken, SVP of IQVIA speaks about the requirements of small biopharma clinical development at the SCOPE 2023 conference in Orlando, FL.

Murray L. Aitken, SVP of IQVIA speaks about how biopharma companies can take advantage of present opportunities at the SCOPE 2023 conference in Orlando, FL.

Seagen, an oncology biotech, emphasizes personalization as part of its DE&I strategy.

Dr. Sean Bohen, CEO of Olema Oncology, discusses his career and significant contributions to the clinical research and development of numerous oncology drugs that received regulatory approval for various indications. Plus a look at Olema, how they operate, and challenges they face.

Dr. Harsha Rajasimha, Founder and Chairman of IndoUSrare, discusses the emotional reason behind founding the non-profit, programs they offer that are helping rare disease parents/patients, rare disease research in India, and much more.

Dan Brenner, Founder and CEO of 1nHealth, discusses his path into clinical research and patient recruitment, the Gold Eagle Next Generation Board, what millennials/next generations want from organizations they buy from or invest in, how industry can best harness patient data to accurately predict recruitment timelines, and much more.

Jane Myles, Vice President, Clinical Trial Innovation at Curebase, discusses her current role, what led her there, and challenges their clients face with DCTs.

Chief Science Officer at Unlearn.AI, Dave Miller, discusses digital twins, their pros and cons for the industry, and developments in Bayesian design and adaptive trials for CDER and CBER.

Ukraine invasion tests the resiliency and quick action of CROs and sponsors.

Susan Wood, president and CEO of VIDA Diagnostics, discusses her journey into healthcare from an engineering path, changes in the field of imaging, virtual control arms, and much more

Todd Luckritz, Associate Director, Patient Solutions at Myonex, recently left Mayo Clinic as the lead pharmacist for its clinical research programs. In this podcast, Luckritz discusses his journey “bringing protocols to life,” the joy of interacting with patients, and the frustrations with sourcing that led him to make a difference at Myonex.

Paula Brown Stafford, CEO of Novan, came to her role via increasing clinical development role responsibilities with Quintiles, now IQVIA. In this podcast, she reflects on her professional experiences, her achievements and her advice for clinical trials professionals.

Dr. Shalaan Beg, VP of Oncology for Science 37, discusses his approach to reducing the time to trial activation at an NCI designated cancer center, how to ensure a diverse representation in clinical trials, and his opinion on decentralized and hybrid trials.

Christine McSherry, CEO of Casimir and Mindy Leffler, President and Chairman of Casimir, now a part of CRO Emmes, discuss their path to true patient focused drug development based on their experiences raising sons with Duchenne Muscular Dystrophy (DMD). By understanding early and actual measurable endpoints that matter to DMD patients and caregivers, and providing PROs that can capture data that matters, the women hope to influence other diseases and the quality of life for people that have very little time to waste.

Dr. Ian Smith MBE MB ChB.B MedSc(Hons), Founder, Director and Chief Medical Officer of Panthera Biopartners, and Chris Dodd, the company's Chief Commercial Officer, discuss the evolution of the Site Management Organization and Panthera Biopartners, how clinical trials remain mired in underperformance and difficulties, and hybrid trial advancements.

Praduman “PJ” Jain, CEO & Founder, Vibrent Health; Principal Investigator, NIH All of Us Research Program, Participant Technology Systems Center; Principal Investigator, NIH RADx Program, discusses his involvement in the NIH All of Us program, digital health research tools, and more.